8.30AM - 03.40PM EDT | 5.30AM - 12.40PM PDT
9:00 am Preconference Virtual Networking
Overcoming Regulatory Restrictions at Home and Abroad
9:30 am FDA Regulation of Cannabinoid Pharmaceuticals – Breaking Down All Possible Routes to Approval
Synopsis
9:50 am The International Drug Control Landscape for Cannabinoid Derived Pharmaceuticals
Synopsis
10:10 am Rx and Non-Rx Cannabinoids: A Regulatory Framework for Market
Synopsis
10:30 am Live Presenter Q&A
10:50 am Morning Break & Virtual networking
11:20 am Case Study: Brazilian Cannabis Regulation and its Impact for the Companys’ Clinical Trials Pipeline
Synopsis
11:40 am Key Regulatory Takeaways in Developing a Cannabinoid Pharmaceutical Development Strategy
Synopsis
12:00 pm Live Presenter Q&A
Achieving Market Exclusivity and Building an IP Strategy
12:20 pm Cannabinoid-Related IP: Novelty Amidst a Treasure Trove
Synopsis
12:40 pm Live Presenter Q&A
12:50 pm Panel Discussion: Designing an IP Strategy from the Ground Up that Will Give you the Edge
Synopsis
1:20 pm Lunch & Virtual Networking
Breaking Down Barriers to Investment
1:50 pm Panel Discussion: Dispelling Common Misconceptions About Biotech Funding and Applying this Understanding to Cannabinoid Pharmaceuticals
14.30 Afternoon Virtual networking Break
Translational Clinical Development Track
Commercial Pipeline Development and Manufacturing Track
Efficiently take your cannabinoid formulation from in vivo/vitro testing into the clinic, with confidence
Maximizing the value that your therapeutics offer and ensuring quality in your supply chain
3.00 pm Assessing the Potential Clinical Value of the Next Hopefuls in Cannabinoid Pharmaceutical APIs: CBG, CBN and THCA
- Preclinical evidence for the use of novel minor cannabinoids
- Minor cannabinoid safety and toxicity
- Where is the clinical evidence?
Hunter Land, Associate Director of Cannabinoid Research, Canopy Growth Corporation
3.00 pm Analyzing Clinical Data to Extract Insights into Clinical Endpoints and Mechanism of Action
- Tetra Biopharma is currently pursuing a variety of clinical programs employing inhaled synthetic cannabinoid derived pharmaceuticals, including for pain and oncology indications
- Analysis, interpretation and comparison of data across programs also connects these and is invaluable for the design of future studies and in decision making when it comes to future indications to pursue
Aurélia De Pauw, Vice President, Clinical Programs and Medical Affairs, Tetra Bio Pharma
3.20 pm How can you Accelerate and Support the Preclinical & Translational Development of Therapeutics in this Space?
- The cannabinoid derived drug development industry is facing multiple roadblocks impeding the demonstration of clinical utility in pipeline candidates
- Highlight your proven track record facilitating and accelerating the delivery of therapeutics with target efficacy and safety profiles
- Position yourself as the partner of choice in this fast paced and expanding industry
Enquire today to find how you can get involved and
contact:
Nicholas Ramovic, Partnerships Director
@: sponsor@hansonwade.com
T: (+1) 617 455 4188
3.20 pm Strategically Selecting New Indications to Pursue
- Which data can be used to inform future therapeutic indications to pursue
- Clinical trial data for expanding the indications of existing pharmaceuticals
- Regulatory considerations in cannabis-based pharmaceutical development
Boaz Hirshberg, Executive Vice President, Chief Medical Officer, Head of Global Development, BOLPharma